Day one stream two

Please enable javascript to see more information on speakers

2pm	De-risking strategies for CV drug development including the use of novel imaging modalities to evaluate pre-clinical and clinical safety findings David Kallend Dr David Kallend trained in medicine at King’s College London and King’s College Hospital, qualifying with an MBBS from the University of London in 1988. Following this he trained in surgery, predominantly at the Royal Postgraduate Medical School... more.. › David Kallend, Global Clinical Leader and PD Group Medical Director, Roche
2.30pm	Safety challenges for vaccines Felix Arellano Dr Arellano is a medical doctor who is currently working as Vice-President, Head of Safety and Pharmacovigilance at GSK Biologicals Belgium. He completed his M.D. degree from the University of Madrid, Spain, followed by training in ... more.. › Felix Arellano, VP, BSCP Global Vaccine Development, GlaxoSmithKline Vaccines
3pm	Challenges in safety assessments for geriatric patients Philippe Guillet Following his medical studies at the Pitié-Salpétrière Hospital, Dr Philippe Guillet specialized in Geriatrics and Gerontology and practiced for about 10 years at the Charles-Foix Hospital, the largest Geriatric Hospital in France. He then joined... more.. › Philippe Guillet, Senior Director, Worldwide Head HealthCare Technologies for Aging, Sanofi